Weber, P. ; Künstner, A.* ; Hess J. ; Unger, K. ; Marschner, S. ; Idel, C.* ; Ribbat-Idel, J.* ; Walz, C.* ; Rietzler, S.* ; Valeanu, L.* ; Herkommer, T. ; Kreutzer, L. ; Klymenko, O.* ; Kirchner, T.* ; Ganswindt, U. ; Walch, A.K. ; Sterr, M. ; Lickert, H. ; Canis, M.* ; Rades, D.* ; Perner, S.* ; Berriel Diaz, M. ; Herzig, S. ; Wollenberg, B.* ; Busch, H.* ; Zitzelsberger, H.
Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer.
Clin. Cancer Res. 28, 1038-1052 (2022)
PURPOSE: The genetic relatedness between primary and recurrent head and neck squamous cell carcinomas (HNSCC) reflects the extent of heterogeneity and therapy-driven selection of tumor subpopulations. Yet, current treatment of recurrent HNSCC ignores the molecular characteristics of therapy-resistant tumor populations. EXPERIMENTAL DESIGN: From 150 tumors, 74 primary HNSCCs were RNA-sequenced and 38 matched primary/recurrent tumor pairs were both, whole-exome and RNA-sequenced. Transcriptome analysis determined the predominant classical (CL), basal (BA) and inflamed-mesenchymal (IMS) transcriptional subtypes according to an established classification. Genomic alterations and clonal compositions of tumors were evaluated from whole-exome data. RESULTS: While CL and IMS subtypes were more common in primary HNSCC with low recurrence rates, the BA subtype was more prevalent and stable in recurrent tumors. The BA subtype was associated with a transcriptional signature of partial epithelial-to-mesenchymal transition (p-emt) and early recurrence. In 44% of matched cases, the dominant subtype changed from primary to recurrent tumors, preferably from IMS to BA or CL. Gene set enrichment analysis identified upregulation of Hypoxia, p-emt and radiation resistance signatures and downregulation of tumor inflammation in recurrences compared to index tumors. A relevant subset of primary/recurrent tumor pairs presented no evidence for a common clonal origin. CONCLUSIONS: Our study showed a high degree of genetic and transcriptional heterogeneity between primary/recurrent tumors, suggesting therapy-related selection of a transcriptional subtype with characteristics unfavorable for therapy. We conclude that therapy decisions should be based on genetic and transcriptional characteristics of recurrences rather than primary tumors to enable optimally tailored treatment strategies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Squamous-cell Carcinoma; Genetic-heterogeneity; Oropharyngeal Cancer; Local Recurrence; Open-label; Hpv; Multicenter; Evolution; Genomics; Insights
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2022
Prepublished im Jahr
2021
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
1078-0432
e-ISSN
1557-3265
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 28,
Heft: 5,
Seiten: 1038-1052
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
American Association for Cancer Research (AACR)
Verlagsort
615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30205 - Bioengineering and Digital Health
90000 - German Center for Diabetes Research
30201 - Metabolic Health
30505 - New Technologies for Biomedical Discoveries
Forschungsfeld(er)
Radiation Sciences
Enabling and Novel Technologies
Helmholtz Diabetes Center
PSP-Element(e)
G-501000-001
G-521800-001
G-500390-001
G-501900-231
G-502300-001
G-501900-253
G-501900-251
A-630600-001
Förderungen
Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy
Helmholtz Initiative on Personalized Medicine (iMed; project "Integrative Molecular Landscape of HNSCC")
BMBF
Copyright
Erfassungsdatum
2022-01-21